The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

Pediatric asthma treatment

Pediatric asthma treatment — long-term control based on spacer-assisted MDI delivery and the MART approach.

Management of childhood asthma presenting with wheezing, chronic cough, and shortness of breath, using spacer-assisted inhaler therapy, maintenance controller medications, and when appropriate, the MART (Maintenance and Reliever Therapy) approach.

Indication

  • Recurrent wheezing, dry cough, and exertion-related shortness of breath
  • Nocturnal or early-morning awakening cough and chest tightness
  • Recurrent asthma attacks triggered by upper respiratory tract infections
  • Variable airflow limitation on spirometry or a positive bronchodilator response
  • Symptoms triggered by exercise, allergens, cold air, or tobacco smoke exposure
  • Increased attack frequency or loss of control in a previously diagnosed child

Preparation

  • Detailed history; symptom frequency, nocturnal awakening, attack triggers, and family history are reviewed
  • Spirometry and bronchial provocation/reversibility testing are planned in selected children
  • Co-existing allergic rhinitis, sinusitis, or reflux are screened
  • An age- and adherence-appropriate spacer is selected, with a face mask for younger children
  • Information is provided about indoor triggers such as tobacco smoke, animal dander, and mold

How it's performed

  1. Treatment follows a stepwise approach; low-dose inhaled corticosteroid (ICS) is preferred initially based on symptom frequency
  2. In adherent children over 5, the MART approach (single inhaler containing ICS + formoterol) may be used for both maintenance and reliever therapy
  3. At all ages, the metered-dose inhaler (MDI) is delivered with a spacer; a face mask is added in younger children
  4. A short-acting beta-2 agonist reliever (e.g., salbutamol) is used only as needed for symptoms
  5. Correct inhaler technique is reviewed at every visit and a written asthma action plan is provided to the family
  6. Treatment of co-existing allergic rhinitis and atopic dermatitis supports asthma control

Post-procedure

  • Treatment response is assessed within 4-6 weeks of initiation; doses are reduced when appropriate
  • Control status is monitored regularly with childhood asthma control tests and attack frequency
  • Growth and development are followed annually
  • Families are informed that low-dose ICS does not have a meaningful permanent effect on growth; uncontrolled asthma and frequent attacks have a greater impact
  • Treatment plans are reviewed in advance during seasonal exacerbation periods

Risks

  • Oral candidiasis and mild voice changes from inhaled corticosteroids (reduced with spacer use and mouth rinsing)
  • Tremor, palpitations, or restlessness from frequent short-acting bronchodilator use
  • Small, transient slowing of growth velocity with high-dose, long-term use
  • Uncontrolled asthma and frequent attacks due to non-adherence or incorrect inhaler technique

FAQ

Do inhaler medications cause dependence?

No. Asthma medications do not cause dependence; on the contrary, when not used regularly, airway inflammation cannot be controlled and symptoms recur.

Will my child outgrow this condition?

In some children, symptoms decrease or resolve during adolescence; in others, they may continue into adulthood. Regular treatment and trigger avoidance support long-term control.

Is using a spacer essential?

Yes. In children, an MDI alone cannot be used effectively. The spacer increases the amount of medication reaching the lungs and reduces the amount left in the mouth and side effects. A face mask is added for younger children.

Can my child play sports?

Yes. With well-controlled asthma, sports are encouraged. For exercise-triggered symptoms, the physician arranges a separate plan for medication to be used before training.

Related Information